2-甲基-1-哌啶-2-丙胺 | 6105-74-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-甲基-1-哌啶-2-丙胺
• 中文别名: 1,1-二甲基-2-哌啶-1-乙胺
• 英文名称: 2-methyl-1-(piperidin-1-yl)propan-2-amine
• 英文别名: 1,1-Dimethyl-2-piperidinoethylamin；1,1-dimethyl-2-piperidin-1-yl-ethylamine；2-methyl-1-piperidino-2-propanamine；1-(2-Amino-2-methyl-propyl)-piperidin；N-(2-Amino-2-methylpropyl)-piperidin；2-methyl-1-piperidin-1-ylpropan-2-amine
• CAS: 6105-74-4
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: IMBNEKOMEDCTCL-UHFFFAOYSA-N

物化性质

• 沸点：
  67 °C
• 密度：
  0.909±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

SDS

Name:	2-Methyl-1-piperidino-2-propanamine Material Safety Data Sheet
Synonym:	None Known
CAS:	6105-74-4

Section 1 - Chemical Product MSDS Name:2-Methyl-1-piperidino-2-propanamine Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6105-74-4	2-Methyl-1-piperidino-2-propanamine	97+	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid immediately.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale. Discard contaminated shoes. Use only with adequate ventilation.
Storage:
Keep container closed when not in use. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6105-74-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 67-70.0 deg C @ 1mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H20N2
Molecular Weight: 156.27

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
None reported.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6105-74-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Methyl-1-piperidino-2-propanamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
IMO
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
RID/ADR
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 6 Keep under nitrogen.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 6105-74-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6105-74-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6105-74-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基-1-哌啶-2-丙胺 在 铜 、 potassium carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 48.0h， 生成 N-(1,1-Dimethyl-2-piperidinoethyl)-N-(2-pyridyl)-propionamid
  参考文献：
  名称：

  Geiger; Wollweber, European Journal of Medicinal Chemistry, 1982, vol. 17, # 3, p. 207 - 215

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(2-甲基-2-硝基丙基)哌啶 在 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 1.0h， 以100%的产率得到2-甲基-1-哌啶-2-丙胺
  参考文献：
  名称：

  [EN] NOVEL C28-ANALOGUES WITH C3-MODIFICATIONS OF TRITERPENE DERIVATIVES AS HIV INHIBITORS
  [FR] NOUVEAUX ANALOGUES DE C28 À MODIFICATIONS EN C3 DE DÉRIVÉS TRITERPÉNIQUES À UTILISER EN TANT QU'INHIBITEURS DU VIH

  摘要：

  本发明涉及具有新型C28类似物和三萜衍生物的C3修饰的化合物的公式(I)；或药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的水合物、互变异构体、立体异构体、前药、组合物或其组合物，其中R1、R2、R3、R4、R5、R6、R7、R8、X和Z如本文所定义。本发明还涉及包含公式(I)化合物的药物组合物，用于治疗病毒性疾病，特别是HIV介导的疾病。

  公开号：

  WO2017025901A1

文献信息

• [EN] NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS D'AMIDE SUBSTITUÉS BÉTULINIQUES UTILISÉS COMME INHIBITEURS DU VIH
  申请人：HETERO RESEARCH FOUNDATION

  公开号：WO2017017630A1

  公开（公告）日：2017-02-02

  The present invention relates to novel betulinic substituted amide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y, Z1, Z2, Z3 and are Formula (II) as defined herein. The invention novel betulinic substituted amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

  本发明涉及新的取代苦杏仁酸酰胺化合物的化学式(I)；以及其药用盐，其中R1、R2、R3、R4、R5、R6、R7、R8、X、Y、Z1、Z2、Z3和在此定义的化学式(II)。该发明涉及新的取代苦杏仁酸酰胺衍生物、相关化合物和药物组合物，用于治疗病毒性疾病，特别是HIV介导的疾病。
• NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES
  申请人：Chen Li

  公开号：US20090203681A1

  公开（公告）日：2009-08-13

  The present invention provides novel compounds of the general formula (I) and pharmaceutically acceptable salts thereof, processes for the manufacture of these novel compounds and medicaments containing such compounds. The compounds of the present invention show anti-proliferative and differentiation-inducing activity, which results in inhibition of tumor cell proliferation, induction of apoptosis and inhibition of invasion. The invention also covers the use of such compounds for the treatment of diseases such as cancer and for the manufacture of corresponding medicaments.

  本发明提供了一般式（I）的新化合物及其药学上可接受的盐，制备这些新化合物的方法以及含有这些化合物的药物。本发明的化合物表现出抗增殖和诱导分化活性，导致抑制肿瘤细胞增殖、诱导凋亡和抑制侵袭。该发明还涵盖了利用这些化合物治疗癌症等疾病以及制造相应药物的用途。
• [EN] NOVEL C28-ANALOGUES WITH C3-MODIFICATIONS OF TRITERPENE DERIVATIVES AS HIV INHIBITORS<br/>[FR] NOUVEAUX ANALOGUES DE C28 À MODIFICATIONS EN C3 DE DÉRIVÉS TRITERPÉNIQUES À UTILISER EN TANT QU'INHIBITEURS DU VIH
  申请人：HETERO RESEARCH FOUNDATION

  公开号：WO2017025901A1

  公开（公告）日：2017-02-16

  The present invention relates to compounds of novel C28-analogues with C3- modifications of triterpene derivatives of formula (I); or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, tautomers, stereoisomers, prodrugs, compositions or combination thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, and Z are as defined herein. The present invention also relates to pharmaceutical compositions comprising compounds of formula (I) useful for the treatment of viral diseases and particularly HIV mediated diseases.

  本发明涉及具有新型C28类似物和三萜衍生物的C3修饰的化合物的公式(I)；或药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的水合物、互变异构体、立体异构体、前药、组合物或其组合物，其中R1、R2、R3、R4、R5、R6、R7、R8、X和Z如本文所定义。本发明还涉及包含公式(I)化合物的药物组合物，用于治疗病毒性疾病，特别是HIV介导的疾病。
• [EN] COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION<br/>[FR] COMBINAISONS POUR TRAITEMENT DE MALADIES IMPLIQUANT UNE PROLIFÉRATION CELLULAIRE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2006018182A1

  公开（公告）日：2006-02-23

  The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

  本发明涉及一种用于治疗涉及细胞增殖的疾病的药物组合物。该发明还涉及一种治疗上述疾病的方法，包括共同给药于一种具有以下式(I)的化合物1，其中基团L、R1、R2、R3、R4和R5具有索赔和规范中给定的含义，可选地以其互变异构体、消旋体、对映体、二对映异构体和它们的混合物的形式，以及可选地以药理学上可接受的酸盐、溶剂化合物、水合物、多型、生理功能衍生物或其前药的形式，以及与有效量的活性化合物2和/或辐射治疗共同治疗，其比例提供加成和协同作用，并且结合使用具有以下式(I)的化合物1和有效量的活性化合物2和/或放射治疗用于制备相应的药物组合制剂。
• New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma GmbH Co. KG

  公开号：US20040176380A1

  公开（公告）日：2004-09-09

  The present invention relates to new dihydropteridinones of general formula (I) 1 wherein the groups L and R 1 - R 5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.

  本发明涉及一般式（I）1的新二氢叶酸酮，其中基团L和R1-R5具有索赔和规范中给出的含义，其异构体，制备这些二氢叶酸酮的过程以及其作为药物组合物的用途。